India, Feb. 11 -- Royalty Pharma plc (RPRX), Tuesday announced fourth-quarter financial results, reporting profit of $208 million compared to $494 million in the previous year.
Income and other revenues were $594 million in the quarter compared to last year's $596 million.
Looking ahead, the company expects portfolio receipts of $2.9 billion to $3.050 billion for the fiscal year 2025.
In the pre-market hours, Royalty Pharma's stock is trading at $32.72, up 3.15 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....